Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

AbbVie's New Advanced Parkinson's Treatment Available in Canada

April 10, 2014 10:38 am | News | Comments

AbbVie announced that a new treatment called Duodopa (levodopa/carbidopa intestinal gel) is now available to Canadians with advanced Parkinson's disease. Read more...                        


Hemophilia Drug Maintains Low Bleeding Rates in Children

April 10, 2014 10:34 am | News | Comments

Biogen Idec and Sobi released positive top-line results of the Kids A-LONG Phase 3 clinical study that evaluated the safety and efficacy of Eloctate in children with severe hemophilia A. Read more...            


New Vaccine Hope for Viral Cause of Birth Defects

April 10, 2014 10:25 am | News | Comments

Experts in infection and immunity have made a path-finding discovery that could lead to the development of a vaccine for a health-ravaging virus that affects around 50% of adults in the UK. Read more...              


Have Millions Been Wasted on Flu Drug?

April 10, 2014 10:11 am | News | Comments

British scientists say there isn’t enough evidence to prove the antiviral drug Tamiflu reduces the spread of flu. New study findings question whether governments worldwide were justified in spending millions on the drug during the 2009 swine flu pandemic. Read more...


Erytech Expands Tumor Starvation Development Portfolio

April 9, 2014 1:59 pm | News | Comments

Erytech Pharma announced the addition of a new product development candidate, ERY-MET, to the company’s tumor starvation product pipeline. Read more...                             


Lilly, T1D Exchange Collaborate to Advance Diabetes Care

April 9, 2014 1:54 pm | News | Comments

T1D Exchange and Eli Lilly and Co. announced they have entered into a research collaboration that will enable both organizations to gain deeper, real-world insight about the experience of people with type 1 diabetes. Read more...      


Nektar Reports Positive Preclinical Data for Two Oncology Programs

April 9, 2014 1:48 pm | News | Comments

Nektar Therapeutics announced that positive preclinical data for NKTR-102 and NKTR-214 were presented at the 2014 Annual Meeting of the AACR in San Diego, Calif. Read more...                      


FDA Wants More Info on Forest’s COPD Drug

April 9, 2014 1:38 pm | News | Comments

Forest Laboratories Inc. and Almirall S.A. announced that they have recently received feedback from the FDA regarding the fixed dose combination of aclidinium and formoterol for treatment of COPD. Read more...            


Phase 2 Efatutazone Trial Shows Challenge of Matching Treatment to Population

April 9, 2014 1:29 pm | News | Comments

Researchers hope that new work on a Phase 2 trial of efatutazone with erlotinib in patients with refractory non-small cell lung cancer will allow them to make better future use of the drug or other drugs in its class. Read more...      


FDA Stops Halozyme PEGPH20 Pancreatic Cancer Trial

April 9, 2014 1:05 pm | News | Comments

Halozyme Therapeutics Inc. announced that the FDA informed the company Tuesday that a clinical hold has been placed on patient enrollment and dosing of PEGPH20 in an ongoing Phase 2 trial evaluating PEGPH20 in patients with pancreatic cancer. Read more...


Faking Fluorescence

April 9, 2014 11:05 am | by Takeharu Nagai, Ph.D., Osaka University, Japan | Articles | Comments

The world’s brightest luminescent protein, a discovery dubbed the “Nano-lantern,” is lighting up the future of in vivo imaging– without the use of external light. This could benefit more advanced applications, such as high-throughput drug screening and single-cell tracking in live animals and plants.


Immunotherapy Shows Early Promise Against Advanced Melanoma

April 9, 2014 10:45 am | News | Comments

A new type of immunotherapy that directs patients’ immune responses toward tumor cell killing, IMCgp100, was well tolerated and showed efficacy in some patients with advanced melanoma in a Phase 1 clinical trial. Read more...        


Glucosamine Promotes Longevity in Mice

April 9, 2014 10:35 am | News | Comments

Feeding glucosamine to mice extended their lifespan by almost 10%, reflecting around eight additional years of human lifespan. Moreover, the supplement improved glucose metabolism in elderly mice, indicating that it may provide protection from diabetes. Read more...


Roche Snags New Biopharma Company for Antibiotics Deal

April 9, 2014 10:20 am | News | Comments

Spero Therapeutics LLC, a biopharmaceutical company founded to develop novel therapies for treatment of bacterial infections, has entered into an antibiotics partnership with Roche. Read more...                


Compound Holds Potential to Treat Drug-Resistant Leukemias

April 9, 2014 10:06 am | News | Comments

Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia.  Read more...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.